
Ongoing support to help start and stay on PLUVICTO treatment
Once you and your health care provider decide to begin PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), Novartis Patient Support is here to help.
Once you and your health care provider decide to begin PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), Novartis Patient Support is here to help.
What is the most important information I should know about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration...
What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with: